enGene Therapeutics Inc.
ENGN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001980845
In the last 90 days, enGene Therapeutics Inc. insiders filed 1 open-market purchase and 0 sales; 60 institutions reported holding it in 13F filings for Q2 2026, worth $86.5M in total; no superinvestor holds it.
Other share classesENGNW
Q4 2024 vs. Q3 2024
How the institutions holding enGene Therapeutics Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Of which not filed for Q4 2024 | Q4 2024 | Change |
|---|---|---|---|---|
| Holders | 30 | 1 | 34 | +5 |
| Shares | 34.3M | 160.9K | 41.3M | +7.17M (+21.0%) |
| Value | $227.7M | $1.06M | $274.7M | +$48.0M (+21.2%) |
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (12)
Institutions that held enGene Therapeutics Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| OrbiMed Advisors LLC | 920,339 | $6.12M | 0.13% |
| Goldman Sachs Group Inc | 899,086 | $5.98M | 0.00% |
| Sphera Funds Management Ltd. | 560,000 | $3.72M | 0.69% |
| Vestal Point Capital, LP | 370,000 | $2.46M | 0.15% |
| MAI Capital Management | 70,311 | $467.6K | 0.00% |
| Corton Capital Inc. | 23,601 | $156.9K | 0.09% |
| Pale Fire Capital SE | 14,710 | $97.8K | 0.02% |
| Toronto Dominion Bank | 14,537 | $96.7K | 0.00% |
| Jane Street Group, LLC | 14,038 | $93.4K | 0.00% |
| Vontobel Holding Ltd. | 10,417 | $69.3K | 0.00% |
| UBS Group AG | 1,200 | $7.98K | 0.00% |
| SBI Securities Co., Ltd. | 30 | $200 | 0.00% |
Sold out (7)
Institutions that held enGene Therapeutics Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Janus Henderson Group PLC | 1,000,000 | $6.63M |
| Logos Global Management LP | 800,000 | $5.28M |
| Soleus Capital Management, L.P. | 800,000 | $5.28M |
| Boxer Capital, LLC | 727,900 | $4.80M |
| Vivo Capital, LLC | 678,705 | $4.48M |
| Wolverine Asset Management LLC | 5,574 | $36.8K |
| ADAR1 Capital Management, LLC | 1,970 | $13.0K |
Not filed for Q4 2024 yet (1)
Institutions that held enGene Therapeutics Inc. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Ghost Tree Capital, LLC | 160,898 | $1.06M |